Clinical review

Science, medicine, and the future

Malaria

Christopher J M Whitty, Mark Rowland, Frances Sanderson, Theonest K Mutabingwa

Prevention of malaria requires a combination of laboratory and operational research and political will to provide affordable effective drugs

Introduction

Malaria is one of the leading causes of morbidity and death worldwide, with over 100 million cases and at least a million deaths a year. Most of these deaths are in the poorest regions of the world. Because malaria is a highly complex disease, the diversity of research to prevent and treat it is probably greater than for any other disease. It ranges from modelling climate change and satellite data to predict epidemics through to elucidating the genome sequence of the malaria parasite Plasmodium falciparum and the mosquito vector Anopheles gambiae.¹–⁵ The cultural diversity and poverty of seriously affected populations in Africa, Asia, and South America present particular challenges. Here social science, especially anthropology and economic research, have as important a role as traditional laboratory work. Malaria research is exciting because it is rapidly moving and cross disciplinary. It is also depressing, as the spread of drug resistant parasites, extreme poverty, and the collapse of health services under the impact of HIV or war undermine much of this progress.

Sources and selection criteria

We focus on three areas of malaria research that are developing rapidly and are likely to have an impact in endemic areas in the foreseeable future: prevention of infection by using measures to control vectors, prevention of disease by vaccination, and drug treatment. We supplemented information from published and unpublished data using PubMed and WHO search strategies, directed especially to the identification of good recent reviews.

Preventing transmission by mosquitoes

Basic research has developed several techniques to reduce transmission of malaria by mosquitoes, with theoretical promise long term. Genetic manipulation enables genes for refractoriness to malaria to be inserted into Anopheles mosquitoes, although how these genes would be driven through the mosquito population of Africa remains unclear.⁶ The genome of A gambiae, the principle vector in Africa, has recently been published.⁴ This will open up the range of possible targets and may guide the development of alternative insecticides.⁷ In reality, however, it is in the imaginative use of new ways of deploying two old tools, bed nets and insecticides (especially when they are combined) that advances likely to have an impact in the medium term are occurring.

Insecticide treated nets constitute one of the cheapest, simplest, and most effective methods of preventing morbidity and mortality from malaria in Africa and Asia.⁸ The greatest challenges over the next 10 years will be to expand coverage of affordable nets through public and private sectors to all who need them. This is a big task requiring a diverse alliance between groups unfamiliar with each other: textile industry, pesticide manufacturers, health departments, government regulators, United Nations agencies, non-governmental organisations, distributors, retailers, and community organisations. Special approaches are being developed to reach disadvantaged and poor people, who often need the nets the most. Each cultural and economic setting needs a different

Summary points

<table>
<thead>
<tr>
<th>Malaria kills millions of people every year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic scientific research is advancing rapidly in many disciplines; research with immediate practical applications in endemic countries is moving more slowly</td>
</tr>
<tr>
<td>Novel ways of deploying insecticides and impregnated nets are effective, but new insecticides are needed</td>
</tr>
<tr>
<td>Vaccine research is moving fast, but a vaccine for deploying in endemic areas is some way off</td>
</tr>
<tr>
<td>Increasing drug resistance in South East Asia has been countered with drugs containing artemisins</td>
</tr>
<tr>
<td>As resistance spreads in Africa the key challenge is to find affordable drugs</td>
</tr>
</tbody>
</table>

BMJ 2002;325:1221–4

Gates Malaria Partnership, London School of Hygiene and Tropical Medicine, London WC1B 3DP
Christopher J M Whitty senior lecturer
Mark Rowland senior lecturer
Nuffield Department of Medicine, John Radcliffe Hospital, Oxford OX2 9DJ
Frances Sanderson Lister senior fellow
National Institute of Medical Research, PO Box 96, Dar-es-Salaam, Tanzania
Theonest K Mutabingwa senior lecturer
Correspondence to: C J M Whitty

BMJ 2002;325:1221–4

Summary points

Malaria kills millions of people every year

Basic scientific research is advancing rapidly in many disciplines; research with immediate practical applications in endemic countries is moving more slowly

Novel ways of deploying insecticides and impregnated nets are effective, but new insecticides are needed

Vaccine research is moving fast, but a vaccine for deploying in endemic areas is some way off

Increasing drug resistance in South East Asia has been countered with drugs containing artemisins

As resistance spreads in Africa the key challenge is to find affordable drugs

BMJ 2002;325:1221–4

Gates Malaria Partnership, London School of Hygiene and Tropical Medicine, London WC1B 3DP
Christopher J M Whitty senior lecturer
Mark Rowland senior lecturer
Nuffield Department of Medicine, John Radcliffe Hospital, Oxford OX2 9DJ
Frances Sanderson Lister senior fellow
National Institute of Medical Research, PO Box 96, Dar-es-Salaam, Tanzania
Theonest K Mutabingwa senior lecturer
Correspondence to: C J M Whitty

BMJ 2002;325:1221–4
Vaccines entering clinical trial target distinct life cycle stages of parasite and are designed to elicit different types of immune response.

**Fig 2** Vaccines entering clinical trial target distinct life cycle stages of parasite and are designed to elicit different types of immune response.

The recent evolution and spread of mosquitoes resistant to the successor pyrethroid insecticides is threatening to reduce the potency of nets and to undermine present gains.\(^9\)\(^{10}\) \(^{11}\) A *gambiae* resistant to all known pyrethroids is now found in several southern and western African countries, forcing control programmes in southern Africa to revert to spraying houses with DDT to contain the problem of pyrethroid resistant *Anopheles funestus*.\(^12\) As net usage increases in Africa, further selection of pyrethroid resistance seems inevitable. To preserve the impregnated nets a new type of insecticide must be developed within this decade to replace or supplement the pyrethroids, otherwise the current WHO campaign, Roll Back Malaria, risks going the same way as the Malaria Eradication Programme. New classes of insecticide are not easy to find; no new class has been registered for vector control in over two decades.\(^13\) Industry is always searching for novel chemistry for crop protection, whereas malaria vector control constitutes less than 3% of the global pesticide market, so any new insecticide will be a byproduct of the agrochemical sector. If nothing suitable can be found, older classes of insecticides such as organophosphates and carbamates not previously used on nets but with a safe toxicology profile may have to be revived. Such insecticides are still widely used in agriculture, and field tests show they can kill pyrethroid resistant mosquitoes when used on nets.\(^14\)

**Treated nets have operational limitations**

Nets need to be retreated annually to maintain their efficacy, and this has been one of the major limitations on their use. Few operational systems for retreatment exist in Africa. The most promising solution is the novel “long lasting net,” where the insecticide is able to withstand repeated washing up to the net’s durability of 5 years. The insecticide is incorporated within polyethylene fibre or within a resin that coats the surface of polyester fibres.\(^15\) Bioavailability is achieved by diffusion of insecticide to the surface after washing. Several companies are active in this area, and rapid advances are anticipated. How the logistical issues around delivery and financing of the nets are to be overcome in practice remains to be seen.

Impregnated nets are not appropriate to every situation. Some of the gravest malaria burdens occur in countries undergoing conflict or among refugee populations.\(^9\) New ways of protecting individuals using materials that are already widely used have been successful in this setting. During emergencies safe pyrethroid insecticides (for example, permethrin) may be applied to a variety of surfaces, such as tents and blankets, or incorporated into the fibres of the plastic tarpaulins used as shelter material (fig 1).\(^9\)\(^{15}\)\(^{16}\)\(^{17}\) Such measures have good short term effect and are easy to implement. Pakistan’s solution was to dip cattle in pyrethroid, although this is mainly used in Asia where *Anopheles* mosquitoes feed more readily on cattle than on humans.\(^18\)

**Vaccines**

**Much movement, some progress**

In the 1970s the passive transfer of purified immunoglobulin and administration of irradiated malaria sporozoites were both shown to protect against malaria. Neither solution is practical (the irradiated sporozoite...
“vaccine” requires bites from over 1000 infected mosquitoes over several months to confer protection. They did, however, show that it is possible to generate effective immunity against malaria. The challenge is to mimic these protective responses with a vaccine directed at antigens expressed in one of the three life cycle stages in humans. Figure 2 illustrates this cycle and outlines some of the (multiple) other candidate vaccines entering phase 1 or 2 trials.

**Before vaccine has left liver and invaded red blood cells**

Much of the energy and investment in malaria vaccines has targeted the pre-erythrocytic stage of the parasite. A vaccine aimed at this stage is commercially attractive as it would protect travellers as well as those in endemic areas. RTS.S/AS02 (GlaxoSmithKline) is the first malaria vaccine to offer convincing protection in a clinical trial. In laboratory challenges about 40% of vaccinated people were protected against malaria, and in field trials in the Gambia the vaccine had a 71% efficacy at 2 months. Protection was, however, short lived: in the last 6 weeks of the 15 week follow up, efficacy fell to zero, yielding an overall efficacy of 34%.20

Although RTS.S was designed to elicit antibody responses capable of neutralising circulating parasites, antibody levels correlated only weakly with protection. Evidence shows that T cells are central to protection elicited by vaccines used in the pre-erythrocytic stage. Recently, DNA (as opposed to protein) based vaccines have proved excellent at stimulating the cellular immune response, at least in animal models (fig 3). Immunisation with a DNA plasmid followed by recombinant modified vaccinia Ankara, both encoding a rodent malaria protein, induced complete protection from challenge with sporozoites in mice.21 With these encouraging results, *P felisparum* vaccines based on the same “heterologous prime boost” schedule entered clinical trials in Oxford in 1999. A series of studies on sporozoite challenge are in progress with this immunisation regimen and also with a potentially more immunogenic regimen employing two recombinant poxviruses (AVS Hill, personal communication, 2002). Phase 1 field trials of both the DNA modified vaccinia Ankara and the novel recombinant fowlpox modified vaccinia Ankara prime boost immunisation strategy have already recently been undertaken in the Gambia, with promising results (V Moorthy, personal communication, 2002).

**Once vaccine has invaded red blood cells**

Clinical assessment of potential vaccines to be used in the blood stage have lagged behind those targeting the pre-erythrocytic stages. This is partly because they carry little commercial interest (residents of endemic countries rather than travellers would be the target population) and partly because there is no safe malaria blood stage challenge in humans. This may change however, with the development of polymerase chain reaction techniques to monitor low level parasitaemia. Researchers in Australia have challenged volunteers with low infective doses. Using polymerase chain reaction they successfully monitored the increase of parasitaemia until it was detectable by standard thick film microscopy. The rate of increase of parasitaemia over this period should correlate with the degree of immunity in the blood stage and therefore serve as a relatively safe phase 2 test of a malaria vaccine to be used in the blood stage.22 Several candidate vaccines targeting the blood stage are available (fig 2), all using traditional recombinant protein but with novel adjuvants.

**Vaccines against the mosquito stage of the malaria life cycle**

During the blood stages of malaria infection some parasites differentiate to produce male and female gametocytes; it is these that infect the mosquito. A novel group of transmission blocking vaccines works on the principle that antibodies generated in the human host and directed at gametocyte or ookinete antigens can block parasite development in the mosquito vector when ingested together with parasites in the blood meal. Transmission blocking vaccines can be developed more rapidly than the disease modifying vaccines, as no parasite challenge of volunteers is required. *Anopheles* mosquitoes are fed on infected erythrocytes that have been mixed with serum from immunised individuals. Infection is monitored by dissection of mosquitoes. The first transmission blocking vaccine will shortly be entering clinical trials. It is based on surface proteins of the *P vivax* ookinete and is highly immunogenic in animal studies. The homologous *P falciparum* vaccine should follow soon. The main drawback of transmission blocking vaccines is that benefit would be conferred on the community rather than the vaccinated individual. It is
unlikely that these vaccines would even be used alone rather than as a component of vaccines that target other stages of the life cycle.

Treatment

Drug resistance and affordability are key issues

Although chloroquine still works well for non-falciparum malaria, chloroquine resistant falciparum malaria is now nearly universal, and multidrug resistant malaria is spreading. In South East Asia multidrug resistant malaria is now so widespread that virtually no antimalarial can be used alone reliably. New rapid methods of drug screening hold out the promise of much faster identification of novel antimalarials in the longer term. It is mainly the investigation of older drugs used in novel combinations, however, that has produced a solution in this region. The artemisin group of drugs, derived from a traditional Chinese herbal drug, combined with a variety of partner drugs, some well known (for example, mefloquine) and some novel (for example, lumefantrine) have proved highly effective even in multidrug resistant malaria. Artinisin combinations may delay and possibly reverse the development of drug resistance through a variety of mechanisms. A rolling programme of efficacy and operational trials in Thailand and Vietnam mean that clinical research has kept pace with the advance of drug resistance in this region.

Multidrug resistant malaria is not yet a major problem in east and central Africa. The current target of research is finding an affordable drug that works. Because of economic constraints the successor drug to chloroquine has been sulfadoxine-pyrimethamine (Fansidar; Roche). Several countries have recently changed to this as first line treatment. Even before they did, however, parasitological resistance of over 20% to sulfadoxine-pyrimethamine in east Africa was common, and over 40% has been reported in some areas. The situation is likely to be critical within a couple of years. Doubtless, artemisin containing combinations would work as well as they do in South East Asia in case management, but cost is a problem. Chloroquine and sulfadoxine-pyrimethamine cost around 15 cents (10p) for a treatment course, and artemisin combinations cost over $1 (64p). Since the average family gets many episodes of malaria a year, and household incomes of less than $10 (£6.40) a month are not uncommon, this raises serious problems. Scientific research is contributing in two different ways. One is in bringing forward novel but affordable drugs—a pioneering partnership between GlaxoSmithKline, WHO, and academic institutions has fast tracked a relatively cheap new antimalarial, dapsone-chlorproguanil (Lapdap), based on combining two older drugs. The other is in operational research, applied anthropology, and economics in trying to determine the best way to deliver an effective existing drug at a cost and in a way most can afford. It is likely, however, that long term subsidy will be essential to provide effective, affordable antimalarial drug combinations for all. This is a political rather than a scientific problem, and until it is solved, making the best use of monotherapy against steadily increasing resistance remains an important practical scientific goal.

MR also works for HealthNet International, Pakistan.

Competing interest: None declared.

Additional educational resources

plasmodb.org/~the Plasmodium falciparum genome
www.ensembl.org/Anopheles gambiae/~the Anopheles genome project
rbm.who.int/~WHO Roll Back Malaria website (contains many useful links)
wwmalaria vaccine.org—the Malaria Vaccine Initiative
www.mxt.org—Medicines for Malaria Venture

19 Good MF. Towards a blood-stage vaccine for malaria: are we following all the leads? Nature Rev Immunol 2001;1:117-25.